BIND Receives $12.4 Mln Financing

strong>BIND Biosciences said Tuesday that it had secured $12.4 million in Series C-1 financing. All of BIND's current investors, including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments, as well as new investor EndeavoUr Vision, contributed to the financing. BIND, of Cambridge, Mass., is a biopharmaceutical company developing drugs to treat serious diseases.

North AmericaUSBriefs